Adherence to isoniazid preventive therapy in children exposed to tuberculosis: A prospective study from Guinea-Bissau

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 12, 2011, Pages 1637-1642

  Gomes, Victor Francisco ^a   Wejse, C ^a,b   Oliveira, I ^a   Andersen, A ^a   Vieira, F J ^c   Carlos, L J ^d   Vieira, C S ^c   Aaby, P ^a   Gustafson, P ^e  

^a Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c National Tuberculosis Referral Hospital (Hospital de Pneumologia Raoul Follereau)   (Guinea-Bissau)

^d Hospital Nacional Simao Mendes   (Guinea-Bissau)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Adherence; Guinea Bissau; Isoniazid preventive therapy; Latent TB; TB exposure

Indexed keywords

ISONIAZID; PYRIDOXINE;

ADOLESCENT; ARTICLE; CHEMOPROPHYLAXIS; CHILD; CONTACT EXAMINATION; CONTROLLED STUDY; DERMATITIS; FEMALE; GUINEA-BISSAU; HEPATOMEGALY; HOME CARE; HUMAN; JAUNDICE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRESCHOOL CHILD; PRIORITY JOURNAL; PRURITUS; SCHOOL CHILD; TREATMENT DURATION; TUBERCULOSIS; VOMITING;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CONTACT TRACING; FEMALE; FOLLOW-UP STUDIES; GUINEA-BISSAU; HOUSING; HUMANS; INFANT; ISONIAZID; MALE; MEDICATION ADHERENCE; PROSPECTIVE STUDIES; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY;

EID: 81455150131     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.10.0558     Document Type: Article

References (38)

1. American Thoracic Society. Chemoprophylaxis for the prevention of tuberculosis. Am Rev Respir Dis 1965; 96: 558-560.
2. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999. Am J Respir Crit Care Med 2000; 161 (4 Pt 2): S221-S247.
3. Ferebee S H. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 1970; 26: 28-106.
4. Jenkins D, Davidson F F. Isoniazid chemoprophylaxis of tuberculosis. Calif Med 1972; 116: 1-5.
5. Comstock G W, Baum C, Snider D E Jr. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the Bethel Isoniazid Studies. Am Rev Respir Dis 1979; 119: 827-830.
6. Chaisson R E. New developments in the treatment of latent tuberculosis. Int J Tuberc Lung Dis 2000; 4 (Suppl 2): S176-S181. (Pubitemid 32046279)
7. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUATLD trial. Bull World Health Organ 1982; 60: 555-564.
8. Rieder H L. Interventions for tuberculosis control and elimination. Paris, France: International Union Against Tuberculosis and Lung Disease, 2002: pp 127-146.
9. Enarson D, Rieder H L, Arnadottir T, Trébucq A. Management of tuberculosis. A guideline for low-income countries. 5th ed. Paris, France: International Union Against Tuberculosis and Lung Disease, 2000: pp 1-89.
10. Hopewell P C, Pai M, Maher D, Uplekar M, Raviglione M C. International standards for tuberculosis care. Lancet Infect Dis 2006; 6: 710-725. (Pubitemid 44740086)
11. Marais B J, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev 2007; 8: 124-133. (Pubitemid 46900102)
12. Singh M, Mynak M L, Kumar L, Mathew J L, Jindal S K. Prevalence and risk factors for transmission of infection among children in household contact with adults having pulmonary tuberculosis. Arch Dis Child 2005; 90: 624-628. (Pubitemid 40780726)
13. Marais B J, Gie R P, Schaaf H S, et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004; 8: 392-402. (Pubitemid 38624845)
14. Gedde-Dahl T. Tuberculous infection in the light of tuberculin matriculation. Am J Hygiene 1952; 56: 139-214.
15. Zeidberg L, Gass R, Dillon A, Hutchesson R. The Williamson County Tuberculosis Study. A twenty-four-year epidemiologic study. Am Rev Respir Dis 1963; 87: 1-88.
16. Shingadia D, Novelli V. Diagnosis and treatment of tuberculosis in children. Lancet Infect Dis 2003; 3: 624-632. (Pubitemid 37210226)
17. Marais B J, van Zyl S, Schaaf H S, van Aardt M, Gie R P, Beyers N. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child 2006; 91: 762-765. (Pubitemid 44351177)
18. Donald P R. Childhood tuberculosis: the hidden epidemic. Int J Tuberc Lung Dis 2004; 8: 627-629. (Pubitemid 38625074)
19. Nelson L J, Wells C D. Global epidemiology of childhood tuberculosis. Int J Tuberc Lung Dis 2004; 8: 636-647. (Pubitemid 38625076)
20. Starr M, Sawyer S, Carlin J, Powell C, Newman R, Johnson P. A novel approach to monitoring adherence to preventive therapy for tuberculosis in adolescence. J Paediatr Child Health 1999; 35: 350-354. (Pubitemid 29374420)
21. LoBue P A, Moser K S. Use of isoniazid for latent tuberculosis infection in a public health clinic. Am J Respir Crit Care Med 2003; 168: 443-447. (Pubitemid 37046873)
22. van Zyl S, Marais B J, Hesseling A C, Gie R P, Beyers N, Schaaf H S. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis 2006; 10: 13-18. (Pubitemid 43266271)
23. Gustafson P, Gomes V F, Vieira C S, et al. Tuberculosis in Bissau: incidence and risk factors in an urban community in sub-Saharan Africa. Int J Epidemiol 2004; 33: 163-172. (Pubitemid 38500173)
24. Wejse C, Gomes V F, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2009; 179: 843-850.
25. Narayan S, Mahadevan S, Serane V T. Keith Edwards Score for diagnosis of tuberculosis. Indian J Pediatr 2003; 70: 467-469. (Pubitemid 36834614)
26. Médecins Sans Frontières. Médicaments essentiels: guide pratique d'utilisation. 2nd ed. Paris, France: MSF, 1993: p 78. [French]
27. Barros A J, Hirakata V N. Alternatives for logistic regression in cross-sectional studies: an empirical comparison of models that directly estimate the prevalence ratio. BMC Med Res Methodol 2003; 3: 21.
28. Page K R, Sifakis F, Montes de O R, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med 2006; 166: 1863-1870. (Pubitemid 44455169)
29. Rennie T W, Bothamley G H, Engova D, Bates I P. Patient choice promotes adherence in preventive treatment for latent tuberculosis. Eur Respir J 2007; 30: 728-735. (Pubitemid 351194834)
30. Levesque J F, Dongier P, Brassard P, Allard R. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis 2004; 8: 711-717. (Pubitemid 38750206)
31. Coly A, Morisky D. Predicting completion of treatment among foreign-born adolescents treated for latent tuberculosis infection in Los Angeles. Int J Tuberc Lung Dis 2004; 8: 703-710. (Pubitemid 38747146)
32. Spyridis N P, Spyridis P G, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45: 715-722. (Pubitemid 47378885)
33. Zar H J, Cotton M F, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334: 136.
34. Schaaf H S, Parkin D P, Seifart H I, et al. Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. Arch Dis Child 2005; 90: 614-618. (Pubitemid 40780724)
35. Martinez S A, Calpe Calpe J L, Llavador R G, Ena M J, Calpe A A. Primary prevention and treatment of latent tuberculosis infection with isoniazid: efficacy of a control program, 1997-2002. Arch Bronconeumol 2005; 41: 27-33. (Pubitemid 40293313)
36. Garibaldi R A, Drusin R E, Ferebee S H, Gregg M B. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis 1972; 106: 357-365.
37. Kopanoff D E, Snider D E Jr, Caras G J. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001. (Pubitemid 8380195)
38. Stephenson B J, Rowe B H, Haynes R B, Macharia W M, Leon G. The rational clinical examination. Is this patient taking the treatment as prescribed? JAMA 1993; 269: 2779-2781. (Pubitemid 23154254)